Brunetto MR, Carey I, Maasoumy B, et al. - This study was intended to evaluate the diagnostic ability of the new hepatitis B core‐related antigen (HBcrAg) assay. Researchers conducted a retrospective anonymized data analysis in a multicenter European (nine centers and six countries) cohort of 1,582 consecutive HBsAg‐positive/HBeAg‐negative individuals classified according to EASL guidelines into the following groups: 550 chronic hepatitis B (CHB), 710‐HBeAg‐negative infection, and 322‐GZ (grey‐zone, hepatitis B virus (HBV)‐DNA < 20 000 IU/mL). The results of this study demonstrate that, independently of HBV genotype, HBcrAg assay exhibited high diagnostic performance in the accurate single‐point identification of individuals with HBeAg‐negative CHB. Future prospective studies were needed to confirm its diagnostic role in clinical practice. In CHB and GZ, HBsAg serum levels (HBsAgsl) were similar but they were lower in ENI. The optimal HBcrAg serum levels (HBcrAgsl) cut‐off to distinguish CHB from ENI was 3.14 logU/mL. HBcrAgsl were associated with HBV genotypes but using genotype‐specific cut‐offs, HBcrAg DA remained unchanged with overlapping 95% CI.